Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphoma × eribulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 40 Neoplasms 12 Neoplasm Metastasis 8 Sarcoma 6 Triple Negative Breast Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Prostatic Neoplasms 2 Liposarcoma 2 Leiomyosarcoma 2 Inflammatory Breast Neoplasms 2 Carcinoma 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasm, Residual 1 Metastatic Urothelial Cell Cancer 1 Lymphoma 1 Lung Neoplasms 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1

Interventions

Rituximab 150 Cyclophosphamide 137 Vincristine 61 Etoposide 61 fludarabine phosphate 60 Doxorubicin 58 Prednisone 56 Filgrastim 50 Cytarabine 46 fludarabine 44 Methotrexate 44 Melphalan 44 Busulfan 42 Whole-Body Irradiation 38 Tacrolimus 33 Mycophenolic Acid 33 Granulocyte Colony-Stimulating Factor 31 Radiotherapy 27 Antilymphocyte Serum 27 Peripheral Blood Stem Cell Transplantation 25 Dexamethasone 24 Carmustine 22 Stem Cell Transplantation 20 Lenalidomide 19 Bortezomib 19 Cyclosporine 18 Gemcitabine 17 thymoglobulin 16 Calcium Dobesilate 16 Alemtuzumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02171260 2019-01-15

BOLD 113

Eisai Inc.

Phase 1 Completed

23 enrolled 22 charts

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡